Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Ernexa Therapeutics Inc. (ERNA)

7.12 -0.70 (-8.95%)
As of 11:30:55 AM EDT. Market Open.
Chart Range Bar
Loading chart for ERNA
  • Previous Close 7.82
  • Open 7.69
  • Bid 7.00 x 100
  • Ask 7.11 x 100
  • Day's Range 6.93 - 8.11
  • 52 Week Range 3.18 - 101.25
  • Volume 755,095
  • Avg. Volume 1,270,901
  • Market Cap (intraday) 8.303M
  • Beta (5Y Monthly) 1.89
  • PE Ratio (TTM) --
  • EPS (TTM) -56.00
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

www.ernexatx.com

5

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News: ERNA

View More

Performance Overview: ERNA

Trailing total returns as of 5/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ERNA
76.27%
S&P 500 (^GSPC)
7.93%

1-Year Return

ERNA
90.51%
S&P 500 (^GSPC)
30.45%

3-Year Return

ERNA
99.39%
S&P 500 (^GSPC)
78.54%

5-Year Return

ERNA
100.00%
S&P 500 (^GSPC)
74.56%

Earnings Trends: ERNA

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY22
Revenue --
Earnings --

Q4

FY21

Q1

FY22

Q2

FY22

Q3

FY22

-8M
-6M
-4M
-2M
0

Statistics: ERNA

View More

Valuation Measures

Annual
As of 5/4/2026
  • Market Cap

    4.36M

  • Enterprise Value

    2.97M

  • Trailing P/E

    0.00

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.28k

  • Price/Book (mrq)

    1.82

  • Enterprise Value/Revenue

    4.58k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -104.91%

  • Return on Equity (ttm)

    -686.69%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -14.1M

  • Diluted EPS (ttm)

    -56.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.88M

  • Total Debt/Equity (mrq)

    20.41%

  • Levered Free Cash Flow (ttm)

    -4.58M

Compare To: ERNA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: ERNA

Fair Value

7.12 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: